CAJ | 학술논문

目的：比较替考拉宁在合并与未合并粒细胞缺乏血液病感染患者的临床疗效，进一步评价其在血液病患者中的疗效及安全性，为临床治疗提供参考依据。方法收集2012年8月－2014年8月医院血液科应用替考拉宁的291例血液病感染患者临床资料，统计应用替考拉宁的血液病感染患者感染部位、感染来源、病原菌组成、疗效及安全性等；同时回顾性分析替考拉宁在各种血液病及合并与未合并粒细胞缺乏患者中的疗效，采用 SPSS 17．0软件进行统计分析。结果291例血液病感染患者中发生医院感染156例占53．61％，社区感染135例占46．39％；291例血液病感染患者送检标本中共分离出89株病原菌，其中革兰阴性菌占58．43％、革兰阳性菌占26．97％、真菌占14．60％；使用替考拉宁总有效率为77．31％、总不良反应率为2．06％。结论血液病患者特别是在＜60岁未合并粒细胞缺乏的患者可疑革兰阳性菌感染时，选用替考拉宁抗感染可获得较好疗效，进一步证实替考拉宁为一种高效、安全性高的抗菌药物，能够经验性治疗血液系统疾病患者感染。
목적：비교체고랍저재합병여미합병립세포결핍혈액병감염환자적림상료효，진일보평개기재혈액병환자중적료효급안전성，위림상치료제공삼고의거。방법수집2012년8월－2014년8월의원혈액과응용체고랍저적291례혈액병감염환자림상자료，통계응용체고랍저적혈액병감염환자감염부위、감염래원、병원균조성、료효급안전성등；동시회고성분석체고랍저재각충혈액병급합병여미합병립세포결핍환자중적료효，채용 SPSS 17．0연건진행통계분석。결과291례혈액병감염환자중발생의원감염156례점53．61％，사구감염135례점46．39％；291례혈액병감염환자송검표본중공분리출89주병원균，기중혁란음성균점58．43％、혁란양성균점26．97％、진균점14．60％；사용체고랍저총유효솔위77．31％、총불량반응솔위2．06％。결론혈액병환자특별시재＜60세미합병립세포결핍적환자가의혁란양성균감염시，선용체고랍저항감염가획득교호료효，진일보증실체고랍저위일충고효、안전성고적항균약물，능구경험성치료혈액계통질병환자감염。
OBJECTIVE To compare the efficacy of teicoplanin in patients with hematological diseases complicated with or without neutropenia and further investigate its efficacy and safety in patients with hematological diseases so as to provide reference for clinical treatment .METHODS Clinical information was collected from 291 patients with hematological diseases in the hematological department during Aug .2912 to Aug .2014 and these patients were given teicoplanin for treatments .The infection sites ,infection sources ,constitution of pathogens ,efficacy and safety of these 291 cases were summarized and analyzed ,meanwhile ,the efficacy of Teicoplanin in patients accom‐panied with or without neutropenia was retrospectively analyzed .The software SPSS 17 .0 was used for statistical analysis .RESULTS Among the 291 patients with hematological diseases ,156 patients (53 .61% ) got hospital in‐fections and 135 patients (46 .39% ) had community infections .Totally 89 pathogens were isolated from the total 291 cases ,including gram‐negative bacteria accounting for 58 .43% ,gram‐positive bacteria accounting for 26 .97%and fungi accounting for 14 .60% .The total effective rate of teicoplanin was 77 .31% and the total adverse event rate was 2 .06% .CONCLUSION Teicoplanin performed better in patients with hematological disease who were younger than 60 years and without neutropenia who might be infected by gram‐positive bacteria .This study fur‐ther proved that teicoplanin was one of the antibiotic agents with good performance and high safety ,which can be used in the empiric therapy for infections in patients with hematological diseases .